K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

摘要: BACKGROUND Treatment with cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, improves overall and progression-free survival preserves quality of life in patients colorectal cancer that has not responded to chemotherapy. The mutation status K-ras gene tumor may affect response cetuximab have treatment-independent prognostic value. METHODS We analyzed samples, obtained from 394 572 (68.9%) colo rectal who were randomly assigned receive plus best supportive care or alone, look for activating mutations exon 2 gene. assessed whether was associated supportive-care groups. RESULTS Of tumors evaluated mutations, 42.3% had at least one effectiveness significantly (P = 0.01 P<0.001 interaction survival, respectively). In wild-type tumors, treatment as compared alone improved (median, 9.5 vs. 4.8 months; hazard ratio death, 0.55; 95% confidence interval [CI], 0.41 0.74; P<0.001) 3.7 months 1.9 progression 0.40; CI, 0.30 0.54; P<0.001). Among mutated there no significant difference between those treated received respect (hazard ratio, 0.98; P 0.89) 0.99; 0.96). group receiving 1.01; 0.97). CONCLUSIONS Patients bearing did benefit whereas cetuximab. influence on among alone. (ClinicalTrials.gov number, NCT00079066.)